Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response — Stella

Recruiting

Back to Breast Neoplasm Female trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(2 sites)

United States

University of Iowa Health Care/Holden Comprehensive Cancer Center, Iowa City, Iowa

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Key details

Phase

Post-approval study

Sponsor

University of Wisconsin, Madison

Collaborators

National Cancer Institute (NCI)

Enrollment target

~50 participants

Started

March 2017

Primary completion

June 2026

Age range

18 Years and older

Sex

Female only

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov